JRI vs PKBK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile for JRI is critically weak, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental deterioration. While the fund offers an attractive dividend yield of 12.51%, the 90% payout ratio suggests limited sustainability and potential capital erosion. The current price of $12.81 trades at a premium to the growth-based intrinsic value of $12.32, and the technical trend is completely bearish (0/100). Overall, the combination of poor financial health scores and negative price momentum outweighs the high yield.
PKBK presents a compelling value opportunity, trading significantly below its Graham Number ($44.50) and Intrinsic Value ($93.22). While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company's growth metrics are outstanding, with YoY earnings growth of 53.30% and a very low PEG ratio of 0.43. Despite strong fundamentals and a sustainable dividend payout, the stock faces short-term headwinds from a bearish technical trend and significant insider selling.
Compare Another Pair
Related Comparisons
JRI vs PKBK: Head-to-Head Comparison
This page compares Nuveen Real Asset Income and Growth Fund (JRI) and Parke Bancorp, Inc. (PKBK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.